| Lightcalls.com |
|
|
![]() |
for what purpose you should make th...for what purpose you should make this counterpart part of your nutrition program. "Inositol hexaphosphate" may be tricky to pronounce, moreover its wide-ranging health benefits are easy to swallow. Now called [IP.sub.6] (formerly referr to as phytic acid), it is a sugary B vitamin (inositol)/phosphate combination that's generating quite a bit of interest in the nutrition-versus-cancer arena. Liver cancer. freshly in the medical journal, Anticancer Research, Abul-Kalam Shamsuddin, MD PhD and colleagues, at handed their findings using [IP.sub.6] in succession pre-existing human liver cancer enclosed spaces transferred into mice. In this 1998 contemplation Shamsuddin, who is a professor of pathology at the University of Maryland exercise of Medicine, looked specifically at hepatocellular carcinoma -- liver cancer -- and rest that not only did [IP.sub.6] hinder the formation of liver cancer, on the other hand it also reversed existing cancer in these experimental mice. Childhood sarcoma. In the first 1998 Anticancer Research inquiry out of Shamsuddin's lab, a series of studies were carried abroad to see if [IP.sub.6] can do anything against human rhabdomyosarcoma (RMS) a highly malignant -- and most numerous common -- soft-tissue cancer (sarcoma) in children. Shamsuddin, and his arrange found that: (1) [IP.sub.6] detains back the growth of human RM cancer in mice, (2) [IP.sub.6]-treated mice (with transferred, or "xenotransplanted," human RM cancer cells) produc 25-times-smaller tumors in a two-week period, and 49-times reduc tumor size from one side of to the other five weeks. Mammary (breast) cancer. Earlier, in 1995 Shamsuddin published his eventuates using [IP.sub.6] in rats in which mammary cancer had been experimentally brought in succession The researchers showed that [IP.sub.6] plus inositol effectively stoped mammary cancer, which has direct implications for human breast cancer. Where does [IP.sub.6] proceed from? Although it is naturally lay the foundation of in wholegrain cereals, nuts, and se oils, it's difficult to come by sufficient amounts from diet, alone. In viands the phytate is closely confine to protein, making the phytate ripe for destruction by the agency of intestinal enzymes (such as phytase). Supplemental (pure) [IP.sub.6] can be absorbed for use by the agency of the body before the enzyme can obtain to it. to what extent does it work? Well, the exact metabolic mechanisms haven't been completely doped revealed yet, but there are a number of things which we do know about [IP.sub.6] with inositol. First, [IP.sub.6] doesn't kill cancer -- not directly, that is. According to Shamsuddin, in his 1998 part [IP.sub.6] -- Nature's Revolutionary Cancer-Fighter, "[IP.sub.6] causes cancer small rooms to mature and behave like normal cells" As an antioxidant, [IP.sub.6]: (1) screens cell membranes from breakdown, or free-radical-caused "lipid peroxidation"; (2) retains abnormal cell growth in check, blocking or reversing cancer, as needed; and (3) boost the ability of natural killer (NK) small rooms to wipe out cancer cells Interestingly enough, since [IP.sub.6] functions independent of hormone regulation that is, typically, organ-specific (eg breast, prostate, liver), it has potential benefits, Shamsuddin moves for any cancer. REFERENCES Shamsuddin, A.M. [IP.sub.6] -- Nature's Revolutionary Cancer-Fighter. recently made known York: Kensington Books, 1998. Vucenik, I., et al. "Inositol hexaphosphate and inositol inhibit DMBA-induced rat mammary cancer," Carcinogenesis 16(5):1055-8 May 1995 Vucenik, I., et al. "[IP.sub.6] in treatment of liver cancer. I. [IP.sub.6] inhibits produce and reverses transformed phenotype in HepG2 human liver cancer small room line," Anticancer Res 18(6A):408390, Nov.-Dec. 1998 Vucenik, I., et al. "[IP.sub.6] in treatment of liver cancer. II. Intra-tumoral injection of [IP.sub.6] regresse pre-existing human liver cancer xenotransplanted in uncovered mice," Anticancer Res 18(6A):4091-6, Nov.-Dec. 1998 COPYRIGHT 1999 PRIMEDIA Intertec, a PRIMEDIA Company. All Rights Reserved |
![]() |
Other Articles
-Morphotek will collaborat...-Eksigent Technologies nam... -The benefits of outsourci... -Sartorius Corporation ... -In our previous column, w... -Efoora appointed Michael ... -Affymax appointed Anne-Ma... -Traditionally, continuous... -New Brunswick Scientific ... -The German-American firm ... -Don G. Burstyn, formerly ... -American patients are mor... -Summary Prior to va... -BioPharm Editorial Adviso... -Australia agreed to spend... -The Biotechnology Industr... -Ambion, The RNA Company i... -Therapies based on living... -A recent survey found tha... -ViroLogic will acquire Ac... -Cardinal Health named Joh... -One of the greatest chall... -As the president of a sma... -Sweden-based Biovitrum wi... -Nanogen appointed David L... -The Experion Process Know... -Although biomedical resea... -The Supreme Court of Cana... -Netherlands-based DSM Bio... -David A. Smoller joined S... -A few months ago, I wrote... -Panacos Pharmaceuticals w... -Karen K. Vaccaro will res... -Acceleron Pharma appointe... -Two quarterly meetings of... -Illinois-based Abbot Labo... -FKI Logistics announced t... -The following corrections... -It its widest definition,... -UK-based Xcellsyz will li... -Andrew P. Aromando joined... -Invitrogen's comprehensiv... -Last month, we described ... -The Swiss life sciences c... -Protein Design Labs (PDL)... -Model It HNMR, the newest... -Tech transfer, like chang... -QLT and Atrix Laboratorie... -Dendreon announced Christ... -Baxter Pharmaceutical Sol... -The biopharmaceutical ind... -GlaxoSmithKline announced... -Montreal-based Caprion Ph... -Xenova Group recently ann... -Cole-Parmer's new 192-pag... -Over the last decade ther... -Benchmark your facility p... -As biotechnology organiza... -Frederick D. Sancillo, fo... -Insmed acquired a recombi... -Baxter Pharmaceutical Sol... -Model It HNMR, the newest... -DA's regulation 21 CFR Pa... -Robert P. Ryan joined Ath... -A new report from Busines... -Biotest offers a complete... -Swagelok offers a brochur... -Partnering is a global ph... -Human Genome Sciences CEO... -Shorten the process devel... -The licensure of biotechn... -Rodger Currie joined Amge... -The GEA Filtration Model ... -A multi-channel chemistry... -From June 6-9, San Franci... -Skanska USA Building Inc.... -New Brunswick Scientific'... -AVI BioPharma appointed P... -Ambion, The RNA Company, ... -"If you want to be a... -Xcellerex appointed Susan... -Researchers identified th... -Cool Spring Business Park... -In October 2003, Shenzhen... -Laureate Pharma appointed... -After a 6-5 vote by Calif... -QSourcing, a service of Q... -The recent discovery of &... -Affymax added Douglas L. ... -USDA recently approved tw... -BioPharm International is... -Serologicals has released... -This document by Shenzhen... -Robert Bronstein joined A... -Gloucester Gains Fujisawa... -With more than 30 years o... -Pall's SUPRAdisc II depth... -In today's competitive ma... -Protein Design Labs repor... -Charles A. Rice will repl... -AstraZeneca's Faslodex (f... |
| . |